Dr. Aeron Hurt
Honorary
Melbourne School of Population and Global Health
145 Scholarly works
1 Projects
HIGHLIGHTS
2021
Journal article
Burden of influenza B virus infection and considerations for clinical management
DOI: 10.1016/j.antiviral.2020.1049702020
Journal article
Viral burden, inflammatory milieu and CD8( )T-cell responses to influenza virus in a second-generation thiazolide (RM-5061) and oseltamivir combination therapy study
DOI: 10.1111/irv.127762020
Journal article
Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir
DOI: 10.1016/j.antiviral.2020.1048512020
Journal article
The impact of climate and antigenic evolution on seasonal influenza virus epidemics in Australia
DOI: 10.1038/s41467-020-16545-62020
Journal article
Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility
DOI: 10.1371/journal.ppat.10085922020
Journal article
Sequencing B cell receptors from ferrets (Mustela putorius furo)
DOI: 10.1371/journal.pone.02337942018
Research Grant
DEFINING THE ROLES AND TARGETING INTERFERON-EPSILON AS A NEW THERAPY FOR INFLUENZA IN ASTHMA AND COPD
RECENT SCHOLARLY WORKS
2020
Conference Proceedings
Immune responses to an inactivated influenza vaacine in Indigenous Australians
2020
Journal article
Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy
DOI: 10.1016/j.antiviral.2020.1047512020
Journal article
Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission
DOI: 10.1371/journal.ppat.10083952020
Journal article
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018
DOI: 10.1016/j.antiviral.2020.104718